The purpose of this study is to determine if antiepileptic drugs (AEDs) differ in their neurodevelopmental effects. Specifically, do the children of the women with epilepsy differ in their behavioral and cognitive development depending on which AED their mother takes during...
Date First Received: August 8, 2001
Last Updated: December 17, 2007
Verified by: National Institute of Neurological Disorders and Stroke (NINDS), December 2007
Clinical Trial Phase: N/A | Start Date: September 2000
Overall Status: Active, not recruiting
Estimated Enrollment: 331
Brief Summary
Official Title: “Neurodevelopmental Effects of Antiepileptic Drugs II: the NEAD Study”
Condition Keyword(s):
The purpose of this study is to determine if antiepileptic drugs (AEDs) differ in their neurodevelopmental effects. Specifically, do the children of the women with epilepsy differ in their behavioral and cognitive development depending on which AED their mother takes during pregnancy?
Study Type: Observational
Study Design: Family-Based, Prospective
Detailed Clinical Trial Description
This is a prospective investigation enrolling 285 to 380 women with epilepsy during the first two trimesters of their pregnancies. There are 25 clinical centers as well as the database center. The women will be taking one of the following AEDs: carbamazepine, phenytoin, valproate, or lamotrigine. Cognitive and behavioral testing of the child will be done up to the age of 6 years. The study does not change the woman's doctor and does not interfere with the care of the treating physician.
Intervention(s) in this Clinical Trial
- Behavioral: Differential Abilities Scale
- IQ measurement at 3, 4.5 and 6 years of age
- Behavioral: Neuropsychological Testing
- Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age
Arms, Groups and Cohorts in this Clinical Trial
- : Carbamazepine
- Children and their mothers exposed to Carbamazepine monotherapy in utero
- : Phenytoin
- Children and their mothers exposed to phenytoin in utero
- : Lamotrigine
- Children and their mothers exposed to Lamotrigine in utero
- : Valproate
- Children and their mothers exposed to Valproate in utero
Outcome Measures for this Clinical Trial
Primary Measures
- Child IQ as measured by the Differential Abilities Scale at 6 Years of age
- Time Frame: 6 years
Safety Issue?: No
- Time Frame: 6 years
Secondary Measures
- Executive Functioning,Tower-NEPSY
- Time Frame: 6 Years
Safety Issue?: No
- Time Frame: 6 Years
- Linguistic Functioning via Expressive one word vocabulary test and NEPSY subscales
- Time Frame: 6 Years
Safety Issue?: No
- Time Frame: 6 Years
- Visual-Spatial Motor Functioning via NEPSY subscale and Visual-Motor Integration Scale
- Time Frame: 6 Years
Safety Issue?: No
- Time Frame: 6 Years
- Memory via Children's Memory Scale
- Time Frame: 6 Years
Safety Issue?: No
- Time Frame: 6 Years
- Motor Functioning via Grooved Pegboard
- Time Frame: 6 Years
Safety Issue?: No
- Time Frame: 6 Years
- Academic Functioning via Wide Range Achievement Test
- Time Frame: 6 Years
Safety Issue?: No
- Time Frame: 6 Years
- Adaptive Functioning via Adaptive Behavior System -2nd Edition
- Time Frame: 6 Years
Safety Issue?: No
- Time Frame: 6 Years
- Behavior via Behavior Assessment for Children & Parent Stress Index
- Time Frame: 6 Years
Safety Issue?: No
- Time Frame: 6 Years
Criteria for Participation in this Clinical Trial
- Subject must be diagnosed with partial seizures and/or secondary generalization or primary generalized seizures (absence, atonic, myoclonic, and generalized tonic-clonic seizures)
- Subjects must be on either carbamazepine, lamotrigine, phenytoin, or valproate monotherapy.
- Mothers must not have a history of drug abuse (including alcohol) in the last year and have no sequelae of drug abuse.
- Mothers must be able to maintain an accurate seizure diary of major motor seizures
- Subjects must have an IQ greater than or equal to 70 points.
- Subjects must have a history of a negative RPR and HIV.
- Subjects must not have progressive cerebral disease or presence of other major medical illness
- Subjects must not have exposure to known teratogens during pregnancy, except AEDs.
- Subjects must not have poor compliance with prenatal care.
- Subjects must have adequate reading skills to perform the cognitive tests.
Gender Eligibility for this Clinical Trial: Female
Minimum Age for this Clinical Trial: N/A
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: University of Florida
Overall Clinical Trial Officials and Contacts
Kimford J. Meador, M.D. Principal Investigator University of Florida
Related Publications
Citations Reporting Results
Meador KJ, Chadwick D, Clayton-Smith J, Pennell P, Liporace J, Kalayian L, and NEAD Study Group. Antiepileptic drugs in pregnancy: Differences in U.K. and U.S.A. Epilepsia, 2003;44 (Suppl. 9):289.
Meador KJ, Page P, Liporace J, Kalayjian L, NEAD Study Group. Antiepileptic Drugs in Pregnancy. Neurology 2004;62 (Suppl 5):A311.
Meador KJ, Baker GA, Clayton Smith J, Pennell P, Liporace J, Kalayjian L, Kini U, NEAD Study Group. Differential Effects of Antiepileptic Drugs on Serious Adverse Outcomes in Children Exposed In Utero. Epilepsia 2004;45 (Suppl 3):58
Meador KM, Loring DW, Baker G, Smith JC, Pennell P, Liporace J, Kalayjian L, Kini U, NEAD Study Group. Differential and dose dependent effects of in utero antiepileptic drugs. Neurology 2005;64 (Suppl 1):A427
Meador KJ, Baker GA, Finnell RH, Kalayjian LA, Liporace JD, Loring DW, Mawer G, Pennell PB, Smith JC, Wolff MC; NEAD Study Group. In utero antiepileptic drug exposure: fetal death and malformations. Neurology. 2006 Aug 8;67(3):407-12.
Additional Information
Information obtained from ClinicalTrials.gov on October 10, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00021866
Study ID Number: R01NS038455
ClinicalTrials.gov Identifier: NCT00021866
Health Authority: United States: Federal Government
Click here for more information about this study and a list of recruiting centers
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.